Spots Global Cancer Trial Database for sintilimab injection
Every month we try and update this database with for sintilimab injection cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | NCT03987867 | Non-small Cell ... First-line Trea... | CIK cell Sintilimab Inje... Pemetrexed Liposome paclit... Carboplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Perioperative Therapy for Hepatocellular Carcinoma | NCT04653389 | Hepatocellular ... | Sintilimab Inje... TACE Radiotherapy | 18 Years - 75 Years | Zhejiang University | |
| Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | NCT03987867 | Non-small Cell ... First-line Trea... | CIK cell Sintilimab Inje... Pemetrexed Liposome paclit... Carboplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma | NCT03881501 | Hepatocellular ... | 18 Years - 75 Years | Huazhong University of Science and Technology | ||
| Perioperative Therapy for Hepatocellular Carcinoma | NCT04653389 | Hepatocellular ... | Sintilimab Inje... TACE Radiotherapy | 18 Years - 75 Years | Zhejiang University | |
| Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer | NCT04836728 | Non-small Cell ... First-line Trea... | CIK cell inject... Sintilimab Inje... Pemetrexed Albumin paclita... Carboplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer | NCT04326153 | IIIA Stage Non-... | Sintilimab Inje... | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma | NCT03881501 | Hepatocellular ... | 18 Years - 75 Years | Huazhong University of Science and Technology | ||
| A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours | NCT05804526 | Advanced Solid ... | RC88 Sintilimab Inje... | 18 Years - 70 Years | RemeGen Co., Ltd. | |
| Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma | NCT03881501 | Hepatocellular ... | 18 Years - 75 Years | Huazhong University of Science and Technology | ||
| Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | NCT05171660 | Colorectal Canc... | Sintilimab Inje... Control Test | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
